Andreas Hochhaus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7480573/publications.pdf

Version: 2024-02-01

413 papers	59,786 citations	2322 98 h-index	1027 235 g-index
426 all docs	426 docs citations	426 times ranked	25990 citing authors

#	Article	IF	Citations
1	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	27.0	3,227
2	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine, 2006, 355, 2408-2417.	27.0	3,212
3	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine, 2002, 346, 645-652.	27.0	1,899
4	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	1.4	1,743
5	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2251-2259.	27.0	1,497
6	Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 1473.	7.4	1,447
7	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2260-2270.	27.0	1,411
8	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosomeâ€“Positive ALL. New England Journal of Medicine, 2006, 354, 2542-2551.	27.0	1,253
9	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
10	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	1.6	1,188
11	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	1.4	1,184
12	Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 349, 1423-1432.	27.0	1,118
13	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	1.4	1,117
14	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.	1.4	1,096
15	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 2010, 42, 722-726.	21.4	1,034
16	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
17	A Phase 2 Trial of Ponatinib in Philadelphia Chromosomeâ€“Positive Leukemias. New England Journal of Medicine, 2013, 369, 1783-1796.	27.0	944
18	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99, 1928-1937.	1.4	943

#	Article	IF	Citations
19	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 2017, 376, 917-927.	27.0	926
20	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23, 1054-1061.	7.2	808
21	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.	1.4	798
22	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-NaÃ¯ve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology, 2016, 34, 2333-2340.	1.6	724
23	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, 110, 3540-3546.	1.4	688
24	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 2016, 30, 1044-1054.	7.2	685
25	Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer, 2007, 7, 345-356.	28.4	588
26	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007, 109, 2303-2309.	1.4	563
27	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 2002, 100, 1965-1971.	1.4	534
28	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012, 119, 1123-1129.	1.4	520
29	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011, 118, 1208-1215.	1.4	486
30	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 3204-3212.	1.6	458
31	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology, The, 2011, 12, 841-851.	10.7	444
32	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	10.7	444
33	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010, 116, 3758-3765.	1.4	440
34	Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology, The, 2012, 13, 579-588.	10.7	428
35	Chronic myeloid leukaemia. Lancet, The, 2007, 370, 342-350.	13.7	423
36	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, 109, 3207-3213.	1.4	400

#	Article	IF	Citations
37	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 2012, 26, 2197-2203.	7.2	395
38	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	1.4	392
39	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012, 26, 2096-2102.	7.2	383
40	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2014, 123, 494-500.	1.4	364
41	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Blood, 2009, 114, 1126-1126.	1.4	358
42	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237.	1.6	356
43	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	1.4	352
44	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008, 112, 3330-3338.	1.4	350
45	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, 110, 2309-2315.	1.4	349
46	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 2011, 117, 1141-1145.	1.4	344
47	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 2008, 22, 1200-1206.	7.2	341
48	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood, 2007, 109, 4399-4405.	1.4	333
49	Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine, 2006, 12, 1181-1184.	30.7	326
50	Chronic myeloid leukemia and interferon-Î±: a study of complete cytogenetic responders. Blood, 2001, 98, 3074-3081.	1.4	309
51	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-Î± in Newly Diagnosed Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1634-1642.	1.6	307
52	Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs, 2005, 16, 691-707.	1.4	294
53	Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. Journal of Clinical Oncology, 2009, 27, 4204-4210.	1.6	292
54	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111, 1834-1839.	1.4	284

#	Article	IF	Citations
55	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood, 2009, 114, 4944-4953.	1.4	271
56	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	1.6	271
57	The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2. Cancer Research, 2005, 65, 2662-2667.	0.9	269
58	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	27.0	257
59	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011, 118, 6760-6768.	1.4	254
60	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 2010, 95, 232-240.	3.5	231
61	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 2014, 123, 1353-1360.	1.4	231
62	Comprehensive mutational profiling in advanced systemic mastocytosis. Blood, 2013, 122, 2460-2466.	1.4	222
63	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 2007, 110, 727-734.	1.4	218
64	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	10.7	214
65	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 2013, 27, 107-112.	7.2	212
66	Response and resistance in 300 patients with BCRâ€ABLâ€“positive leukemias treated with imatinib in a single center. Cancer, 2005, 103, 1659-1669.	4.1	207
67	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, 115, 1880-1885.	1.4	198
68	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRAâ€“positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	1.4	195
69	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-Î± treatment. Blood, 2008, 111, 1039-1043.	1.4	195
70	Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 2006, 20, 1925-1930.	7.2	184
71	Molecular heterogeneity in complete cytogenetic responders after interferon-Î± therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood, 2000, 95, 62-66.	1.4	181
72	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	1.6	181

#	Article	IF	Citations
73	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood, 2015, 126, 42-49.	1.4	171
74	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood, 2014, 123, 2317-2324.	1.4	167
75	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021, 35, 440-453.	7.2	159
76	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine, 2011, 208, 2163-2174.	8.5	154
77	Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1429-1435.	1.6	153
78	Rac2-MRC-cIIIâ€“generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 2012, 119, 4253-4263.	1.4	147
79	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041.	1.4	147
80	Dasatinib in imatinibâ€resistant or â€intolerant chronicâ€phase, chronic myeloid leukemia patients: 7â€year followâ€up of study CA180â€034. American Journal of Hematology, 2016, 91, 869-874.	4.1	145
81	The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Annals of Hematology, 2014, 93, 81-88.	1.8	142
82	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007, 109, 4686-4692.	1.4	141
83	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	1.4	141
84	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	2.9	139
85	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood, 2007, 109, 2147-2155.	1.4	135
86	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, 2012, 30, 3596-3603.	1.6	134
87	Interferon-Î±, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood, 2003, 101, 259-264.	1.4	131
88	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Research, 2016, 48, 84-91.	0.8	130
89	Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome â€“ a phaseâ€II study. British Journal of Haematology, 2008, 143, 707-715.	2.5	128
90	Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell, 2011, 19, 740-753.	16.8	124

#	Article	IF	Citations
91	Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7444-7449.	7.1	121
92	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosomeâ€negative cells. Cancer, 2007, 110, 1509-1519.	4.1	121
93	Should a platelet limit of 600 Ã— 10⁹/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. British Journal of Haematology, 1998, 100, 15-23.	2.5	119
94	Dasatinib in imatinibâ€resistant or imatinibâ€intolerant chronic myeloid leukemia in blast phase after 2 years of followâ€up in a phase 3 study. Cancer, 2010, 116, 3852-3861.	4.1	115
95	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 2006, 107, 3339-3341.	1.4	113
96	Resistance to Targeted Therapy in Chronic Myelogenous Leukemia. Seminars in Hematology, 2007, 44, 15-24.	3.4	111
97	Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114, 5271-5278.	1.4	109
98	Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1487-1493.	0.8	104
99	Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer. Journal of Clinical Oncology, 2005, 23, 1350-1357.	1.6	100
100	Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica, 2008, 93, 186-192.	3.5	98
101	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica, 2014, 99, 1441-1447.	3.5	97
102	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	7.2	97
103	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 2004, 103, 3480-3489.	1.4	96
104	Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1384-1390.	0.8	96
105	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	1.4	95
106	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	30.7	94
107	Interferon-îœ€ Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. Blood, 1999, 94, 3668-3677.	1.4	91
108	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2013, 121, 3703-3708.	1.4	91

#	Article	IF	Citations
109	Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosomeâ€“Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib. Journal of Clinical Oncology, 2012, 30, 4323-4329.	1.6	90
110	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 2020, 588, 157-163.	27.8	90
111	Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. Journal of Clinical Oncology, 2005, 23, 7583-7593.	1.6	89
112	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell, 2018, 173, 470-484.e18.	28.9	89
113	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 2016, 127, 703-712.	1.4	87
114	The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 2006, 91, 452-9.	3.5	87
115	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 2012, 68, 723-733.	1.9	86
116	Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor Â gene. Haematologica, 2007, 92, 163-169.	3.5	84
117	Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 524-531.	1.6	84
118	Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. Oncology, 2009, 77, 293-299.	1.9	82
119	Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood, 2012, 119, 530-539.	1.4	81
120	Clinical resistance to imatinib: mechanisms and implications. Hematology/Oncology Clinics of North America, 2004, 18, 641-656.	2.2	80
121	Real-Time Quantitative Y Chromosome-Specific PCR (QYCS-PCR) for Monitoring Hematopoietic Chimerism after Sex-Mismatched Allogeneic Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 419-425.	1.8	79
122	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomeâ€positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	4.1	79
123	Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-Î±. Blood, 2001, 97, 3648-3650.	1.4	78
124	An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 4666-4674.	7.0	78
125	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood, 2011, 117, 2935-2943.	1.4	76
126	Response of ETV6-FLT3â€“positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011, 118, 2239-2242.	1.4	75

#	Article	IF	Citations
127	Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2â€PDGFRA fusion gene. Genes Chromosomes and Cancer, 2006, 45, 950-956.	2.8	72
128	Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood, 2007, 110, 1283-1290.	1.4	72
129	JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncology, The, 2007, 8, 658-660.	10.7	72
130	Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica, 2010, 95, 738-744.	3.5	72
131	Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses. Archives of Dermatology, 2007, 143, 736-40.	1.4	71
132	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood, 2012, 119, 5963-5971.	1.4	69
133	Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood, 2013, 121, 378-384.	1.4	68
134	Dasatinib. Recent Results in Cancer Research, 2014, 201, 27-65.	1.8	68
135	Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica, 2010, 95, 1473-1480.	3.5	67
136	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	1.8	67
137	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 2015, 141, 887-899.	2.5	67
138	Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood, 2002, 99, 1766-1775.	1.4	66
139	Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood, 2018, 132, 307-320.	1.4	66
140	Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia. Cell Cycle, 2011, 10, 250-260.	2.6	64
141	Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 733-738.	2.5	63
142	Expert opinionâ€"management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia, 2020, 34, 1495-1502.	7.2	63
143	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica, 2019, 104, 93-101.	3.5	62
144	The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica, 2013, 98, 1510-1516.	3.5	61

#	Article	IF	Citations
145	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. Blood, 2004, 104, 23-23.	1.4	61
146	Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood, 2011, 117, 5600-5606.	1.4	60
147	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80.	1.8	60
148	Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2003, 36, 175-188.	2.8	58
149	Subclones with the t(9;22)/BCRâ€ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. British Journal of Haematology, 2011, 152, 713-720.	2.5	58
150	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia, 2015, 29, 1832-1838.	7.2	58
151	Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology, 2003, 40, 69-79.	3.4	57
152	Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 2007, 109, 1543-1549.	4.1	57
153	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020, 34, 2138-2149.	7.2	55
154	Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood, 2011, 118, 5697-5700.	1.4	53
155	Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. Blood, 2010, 116, 2286-2286.	1.4	53
156	Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression. Seminars in Oncology, 2012, 39, 58-66.	2.2	52
157	Lack of correlation between ABLâ€BCR expression and response to interferonâ€Î± in chronic myeloid leukaemia. British Journal of Haematology, 1996, 92, 684-686.	2.5	51
158	Chronic myelogenous leukemia: molecular and cellular aspects. Journal of Cancer Research and Clinical Oncology, 1998, 124, 643-660.	2.5	51
159	In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica, 2005, 90, 459-64.	3.5	51
160	Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in Hematology, 2003, 40, 69-79.	3.4	50
161	Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study. Clinical Pharmacology: Advances and Applications, 2013, 5, 85.	1.2	50
162	Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2047-2060.	2.5	50

#	Article	IF	Citations
163	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 2020, 34, 2074-2086.	7.2	50
164	Chronic myeloid leukemia: a model for oncology. Annals of Hematology, 2005, 84, 487-497.	1.8	49
165	ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 2008, 93, 1389-1393.	3.5	48
166	Dasatinib. Recent Results in Cancer Research, 2010, 184, 83-102.	1.8	48
167	The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1971-1984.	2.5	48
168	Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 584-591.	0.4	48
169	Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of Hematology, 2017, 96, 1463-1470.	1.8	48
170	Dasatinib. Recent Results in Cancer Research, 2018, 212, 29-68.	1.8	48
171	An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica, 2007, 92, 970-973.	3.5	47
172	Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease. Hematology American Society of Hematology Education Program, 2011, 2011, 128-135.	2.5	47
173	Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Annals of Hematology, 2013, 92, 1345-1350.	1.8	47
174	Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica, 2014, 99, 7-18.	3.5	47
175	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer, 2016, 122, 1398-1407.	4.1	47
176	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137.	7.2	47
177	KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1032-1038.	0.8	46
178	BCRâ€“ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment. Clinical Cancer Research, 2011, 17, 6812-6821.	7.0	46
179	Ponatinib may overcome resistance of <scp>FLT</scp>3â€<scp>ITD</scp> harbouring additional point mutations, notably the previously refractory <scp>F</scp>691I mutation. British Journal of Haematology, 2012, 157, 483-492.	2.5	46
180	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	3.2	46

#	Article	IF	Citations
181	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <scp>PCM1â€JAK2</scp>, <scp>BCRâ€JAK2</scp> and <scp>ETV6â€ABL1</scp> fusion genes. American Journal of Hematology, 2020, 95, 824-833.	11	46
182	Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia: Correlation With Response to Interferon Alfa Therapy. Journal of Clinical Oncology, 2000, 18, 3331-3338.	1.6	45
183	Phase 1 study of INNOâ€406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosomeâ€positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116, 2665-2672.	4.1	45
184	Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 81-89.	2.8	45
185	BCR-ABL Mutations in Chronic Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 997-1008.	2.2	44
186	Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica, 2011, 96, 360-366.	3.5	44
187	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia, 2021, 35, 1344-1355.	7.2	43
188	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	1.4	43
189	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022, 36, 1825-1833.	7.2	43
190	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 2014, 99, 1204-1211.	3.5	42
191	Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Annals of Hematology, 2015, 94, 219-225.	1.8	42
192	Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes and Cancer, 2006, 45, 401-410.	2.8	41
193	Diagnosis and management of chronic myeloid leukemia. Cancer, 2007, 109, 1365-1375.	4.1	41
194	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica, 2008, 93, 765-769.	3.5	41
195	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer, 2010, 116, 1419-1430.	4.1	40
196	Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica, 2007, 92, 834-837.	3.5	39
197	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 1451-1462.	1.3	39
198	ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 2001, 98, 2879-2880.	1.4	38

#	Article	IF	Citations
199	Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica, 2008, 93, 1145-1154.	3.5	38
200	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	7.0	38
201	Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia, 2018, 32, 2046-2049.	7.2	37
202	EZH2 in Myeloid Malignancies. Cells, 2020, 9, 1639.	4.1	37
203	A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica, 2009, 94, 1227-1235.	3.5	36
204	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2017, 35, 175-184.	1.6	36
205	Identification of a MYO18Aâ€PDGFRB fusion gene in an eosinophiliaâ€associated atypical myeloproliferative neoplasm with a t(5;17)(q33â€34;q11.2). Genes Chromosomes and Cancer, 2009, 48, 179-183.	2.8	35
206	Combined Adjuvant Radiochemotherapy With IMRT/XELOX Improves Outcome With Low Renal Toxicity in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1187-1195.	0.8	35
207	Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, 2009, 23, 1628-1633.	7.2	35
208	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia, 2020, 34, 2064-2073.	7.2	35
209	Molecular response of CML patients treated with interferonâ€Î± monitored by quantitative Southern blot analysis. British Journal of Haematology, 1997, 97, 86-93.	2.5	34
210	Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0150632.	2.5	34
211	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. Journal of Cancer Research and Clinical Oncology, 2017, 143, 843-850.	2.5	34
212	High BCRâ€“ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. Clinical Cancer Research, 2017, 23, 7189-7198.	7.0	34
213	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood, 2012, 120, 163-163.	1.4	34
214	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	17.0	33
215	Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. British Journal of Haematology, 2007, 138, 369-373.	2.5	32
216	Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5â€azacytidine and literature review. European Journal of Haematology, 2014, 93, 247-259.	2.2	31

#	Article	IF	Citations
217	Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1965-1969.	2.5	31
218	EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1641-1650.	2.5	31
219	Isoform localization of Dectinâ€1 regulates the signaling quality of antiâ€fungal immunity. European Journal of Immunology, 2017, 47, 848-859.	2.9	31
220	International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Research, 2008, 32, 505-506.	0.8	30
221	Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemotherapy and Pharmacology, 2004, 53, 276-278.	2.3	29
222	Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anti-Cancer Drugs, 2009, 20, 519-524.	1.4	29
223	A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon Â. Haematologica, 2010, 95, 148-152.	3.5	29
224	Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Annals of Hematology, 2012, 91, 1713-1720.	1.8	29
225	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1585-1596.	2.5	29
226	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	3.5	29
227	Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia. Annals of the New York Academy of Sciences, 2003, 996, 26-38.	3.8	28
228	Superparamagnetic iron oxide nanoparticles exert different cytotoxic effects on cells grown in monolayer cell culture versus as multicellular spheroids. Journal of Magnetism and Magnetic Materials, 2015, 380, 27-33.	2.3	28
229	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica, 2017, 102, 1361-1367.	3.5	28
230	Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.. Journal of Clinical Oncology, 2012, 30, 6504-6504.	1.6	28
231	Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood, 2003, 101, 375-375.	1.4	27
232	Standardization of Preanalytical Factors for Minimal Residual Disease Analysis in Chronic Myelogenous Leukemia. Acta Haematologica, 2004, 112, 30-33.	1.4	27
233	Treatment-free remission in FIP1L1-PDGFRAâ€“positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Advances, 2020, 4, 440-443.	5.2	27
234	Atypical mRNA fusions in PMLâ€RARA positive, RARAâ€PML negative acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2010, 49, 471-479.	2.8	26

#	Article	IF	Citations
235	Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Annals of Hematology, 2015, 94, 133-140.	1.8	26
236	Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia, 2020, 34, 2198-2205.	7.2	26
237	Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Annals of Hematology, 2004, 83, 477-480.	1.8	25
238	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 70, 345-350.	2.3	25
239	Response-related predictors of survival in CML. Annals of Hematology, 2015, 94, 227-239.	1.8	25
240	Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Advances, 2018, 2, 1572-1579.	5.2	24
241	Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. Blood, 2013, 122, 653-653.	1.4	24
242	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 2013, 27, 907-913.	7.2	23
243	Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature. Acta Haematologica, 2016, 135, 1-10.	1.4	23
244	The results of imatinib therapy for patients with primary eosinophilic disorders. European Journal of Haematology, 2006, 76, 535-536.	2.2	22
245	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 2018, 32, 1222-1228.	7.2	22
246	Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia, 2020, 34, 2113-2124.	7.2	22
247	Clinical Decision Making in Chronic Myeloid Leukemia Based on Polymerase Chain Reaction Analysis of Minimal Residual Disease. Blood, 1999, 94, 1484-1486.	1.4	21
248	Expression of interferon-Î± (IFN-Î±) receptor 2c at diagnosis is associated with cytogenetic response in IFN-Î±â€“treated chronic myeloid leukemia. Blood, 2001, 97, 3568-3573.	1.4	21
249	Presentation, Treatment, and Analysis of Prognostic Factors of Terminally ill Patients with Gastrointestinal Tumors. Onkologie, 2009, 32, 2-2.	0.8	21
250	Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancerâ€"An Extended Phase I MARGIT and AIO Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 142-147.	0.8	21
251	Older patients with chronic myeloid leukemia (â‰¥65Âyears) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of Hematology, 2014, 93, 1167-1176.	1.8	21
252	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1589-1599.	2.5	21

#	Article	IF	Citations
253	Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anti-Cancer Drugs, 2005, 16, 435-440.	1.4	20
254	Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World Journal of Gastroenterology, 2014, 20, 15820.	3.3	20
255	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clinical Cancer Research, 2016, 22, 4030-4038.	7.0	20
256	Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutationâ€“Results of An Ongoing Multicenter Phase 2/3 Study.. Blood, 2009, 114, 644-644.	1.4	20
257	Minimal residual disease in chronic myeloid leukaemia patients. Best Practice and Research in Clinical Haematology, 2002, 15, 159-178.	1.7	19
258	Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells. Haematologica, 2007, 92, 838-841.	3.5	19
259	Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2016, 142, 317-324.	2.5	19
260	Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).. Blood, 2007, 110, 734-734.	1.4	19
261	LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia. Oncotarget, 2014, 5, 5257-5271.	1.8	19
262	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-Î±. British Journal of Haematology, 1998, 102, 1271-1278.	2.5	18
263	Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 657-670.	2.2	18
264	Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica, 2008, 93, 178-185.	3.5	18
265	Genotyping of 25 Leukemia-Associated Genes in a Single Work Flow by Next-Generation Sequencing Technology with Low Amounts of Input Template DNA. Clinical Chemistry, 2013, 59, 1238-1250.	3.2	18
266	The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica, 2013, 98, 714-717.	3.5	18
267	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 2019, 104, 955-962.	3.5	18
268	YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia, 2022, 36, 426-437.	7.2	18
269	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. Blood, 2012, 120, 1675-1675.	1.4	18
270	Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A. Blood, 2001, 98, 3874-3875.	1.4	17

#	Article	IF	Citations
271	Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opinion on Pharmacotherapy, 2007, 8, 3257-3264.	1.8	17
272	Cause and management of therapy resistance. Best Practice and Research in Clinical Haematology, 2009, 22, 367-379.	1.7	17
273	Current Treatment Concepts of CML. Current Cancer Drug Targets, 2011, 11, 31-43.	1.6	17
274	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology, 2017, 143, 337-345.	2.5	17
275	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American Journal of Hematology, 2019, 94, 1236-1243.	4.1	17
276	Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 â€˜START-Câ€™ Phase II Study.. Blood, 2005, 106, 41-41.	1.4	17
277	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	1.4	17
278	mRNA Expression of Platelet-Derived Growth Factor Receptor-Î² and C-KIT: Correlation With Pathologic Response to Cetuximab-Based Chemoradiotherapy in Patients With Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1544-1550.	0.8	16
279	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 551-558.	1.3	16
280	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 2013, 13, 173.	2.6	16
281	Suitability of Viability Assays for Testing Biological Effects of Coated Superparamagnetic Nanoparticles. IEEE Transactions on Magnetics, 2013, 49, 383-388.	2.1	16
282	Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. Infection, 2016, 44, 175-186.	4.7	16
283	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Research, 2018, 78, 6223-6234.	0.9	16
284	Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.. Blood, 2009, 114, 339-339.	1.4	16
285	Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors â€“ Results of A Multicenter Phase 2/3 Study.. Blood, 2009, 114, 861-861.	1.4	16
286	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 2022, 139, 1080-1097.	1.4	16
287	ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia Research, 2003, 27, 1163-1166.	0.8	15
288	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	3.5	15

#	Article	IF	Citations
289	Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1293-1300.	2.5	15
290	Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). Blood, 2008, 112, 334-334.	1.4	15
291	Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients. Blood, 2014, 124, 4546-4546.	1.4	15
292	Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. Journal of Clinical Oncology, 2012, 30, 6506-6506.	1.6	15
293	Gefitinib in Combination with 5-Fluorouracil (5-FU)/Folinic Acid and Irinotecan in Patients with 5-FU/Oxaliplatin- Refractory Colorectal Cancer: A Phase I/II Study of the Arbeitsgemeinschaft fÃ¼r Internistische Onkologie (AIO). Oncology Research and Treatment, 2006, 29, 563-567.	1.2	14
294	Management of Bcrâ€“Abl-positive leukemias with dasatinib. Expert Review of Anticancer Therapy, 2007, 7, 1529-1536.	2.4	14
295	Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Current Opinion in Hematology, 2010, 17, 91-96.	2.5	14
296	Detection of centrosome aberrations in diseaseâ€unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. European Journal of Haematology, 2010, 85, 139-148.	2.2	14
297	Detection of Drug-Resistant Clones in Chronic Myelogenous Leukemia Patients during Dasatinib and Nilotinib Treatment. Clinical Chemistry, 2010, 56, 469-473.	3.2	14
298	Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Annals of Hematology, 2013, 92, 1071-1077.	1.8	14
299	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3081-3089.	2.5	14
300	Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation. BMC Blood Disorders, 2012, 12, 9.	0.9	13
301	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). Journal of Cancer Research and Clinical Oncology, 2013, 139, 1397-1404.	2.5	13
302	Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035. Blood, 2008, 112, 3226-3226.	1.4	13
303	Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.. Blood, 2010, 116, 3421-3421.	1.4	13
304	Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta OncolÃ³gica, 2005, 44, 168-173.	1.8	12
305	Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. BMC Medical Informatics and Decision Making, 2020, 20, 28.	3.0	12
306	Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.. Blood, 2007, 110, 320-320.	1.4	12

#	Article	IF	Citations
307	Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2008, 112, 3216-3216.	1.4	12
308	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. Blood, 2010, 116, 2291-2291.	1.4	12
309	Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancerâ€“a phase II study. Anti-Cancer Drugs, 2002, 13, 999-1004.	1.4	11
310	Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. Cancer Genetics and Cytogenetics, 2009, 189, 63-67.	1.0	11
311	Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment. Annals of Hematology, 2011, 90, 1353-1355.	1.8	11
312	5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2835-2843.	2.5	11
313	Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-Î±.. Blood, 2005, 106, 1089-1089.	1.4	11
314	Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial. Blood, 2010, 116, 2295-2295.	1.4	11
315	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Blood, 2011, 118, 452-452.	1.4	11
316	PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget, 2018, 9, 9442-9455.	1.8	11
317	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. Blood, 2009, 114, 4272-4272.	1.4	11
318	Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Annals of Hematology, 2011, 90, 473-475.	1.8	10
319	Clonal T-LGL population mimicking leukemia in Feltyâ€™s syndromeâ€”part of a continuous spectrum of T-LGL proliferations?. Annals of Hematology, 2013, 92, 985-987.	1.8	10
320	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1985-1993.	2.5	10
321	The E3 ubiquitin ligase TRAF2 can contribute to TNF-Î± resistance in FLT3-ITD-positive AML cells. Leukemia Research, 2013, 37, 1557-1564.	0.8	10
322	Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1661-1668.	2.5	10
323	Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Hematology, 2017, 22, 93-98.	1.5	10
324	Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). Journal of Cancer Research and Clinical Oncology, 2019, 145, 1645-1650.	2.5	10

#	Article	IF	Citations
325	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia â€“ An Interim Analysis of the Randomized German CML Study IV. Blood, 2008, 112, 333-333.	1.4	10
326	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia, 2022, 36, 1834-1842.	7.2	10
327	Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drugs, 2005, 16, 39-45.	1.4	9
328	Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin. Anti-Cancer Drugs, 2009, 20, 75-78.	1.4	9
329	Annexin and Survivin in Locally Advanced Rectal Cancer: Indicators of Resistance to Preoperative Chemoradiotherapy?. Onkologie, 2010, 33, 439-444.	0.8	9
330	The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. Journal of Cancer Research and Clinical Oncology, 2013, 139, 605-615.	2.5	9
331	Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 829-837.	2.5	9
332	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1225-1233.	2.5	9
333	Therapy-free remission in chronic myeloid leukemia: possible mechanism. Expert Review of Hematology, 2018, 11, 269-272.	2.2	9
334	Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.. Blood, 2006, 108, 748-748.	1.4	9
335	Complete Remission After Treatment With Single-Agent Ofatumumab in a Patient With High-Risk Leukemic Mantle-Cell Lymphoma. Journal of Clinical Oncology, 2013, 31, e312-e315.	1.6	8
336	Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. Journal of Cellular and Molecular Medicine, 2020, 24, 2942-2955.	3.6	8
337	Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. Blood, 2008, 112, 184-184.	1.4	8
338	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq1 1 0 rgBT /Overlock 1	1.4	8
339	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. Blood, 2014, 124, 4552-4552.	1.4	8
340	Resistance to imatinib in chronic myelogenous leukemia: Mechanisms and clinical implications. Current Hematologic Malignancy Reports, 2008, 3, 72-79.	2.3	7
341	Cancer Patients and the Internet: A Survey of the â€˜Quality of Lifeâ€™ Working Groups of the Arbeitsgemeinschaft fÃ¼r Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft fÃ¼r GynÃ¤kologische Onkologie. Onkologie, 2011, 34, 435-440.	0.8	7
342	Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?. Blood, 2012, 119, 2965-2966.	1.4	7

#	Article	IF	Citations
343	Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of Cancer Research and Clinical Oncology, 2012, 138, 203-212.	2.5	7
344	Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany. Annals of Hematology, 2013, 92, 825-830.	1.8	7
345	Optimizing tolerability of TKI therapy in CML. Blood, 2014, 123, 1284-1285.	1.4	7
346	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2603-2610.	2.5	7
347	Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era â€“ Evaluation of Response and Resistance. Acta Haematologica, 2004, 112, 85-92.	1.4	6
348	Suitability of the PAXgeneâ„¢ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia. Clinical Chemistry and Laboratory Medicine, 2008, 46, 318-22.	2.3	6
349	Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy. Seminars in Hematology, 2009, 46, S11-S15.	3.4	6
350	The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. Annals of Hematology, 2011, 90, 365-366.	1.8	6
351	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2059-2066.	2.5	6
352	Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2511-2519.	2.5	6
353	CML - Not only BCR-ABL1 matters. Best Practice and Research in Clinical Haematology, 2020, 33, 101194.	1.7	6
354	Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction between Breast Cancer and Chronic Myeloid Leukemia. Cells, 2020, 9, 444.	4.1	6
355	Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients.. Blood, 2004, 104, 1013-1013.	1.4	6
356	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2013, 122, 652-652.	1.4	6
357	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
358	AraC-based pharmacotherapy of chronic myeloid leukaemia. Expert Opinion on Pharmacotherapy, 2001, 2, 1129-1135.	1.8	5
359	Paradoxical MAPKâ€activation in response to treatment with tyrosine kinase inhibitors in CML: Flow cytometry loses track. Cytometry Part B - Clinical Cytometry, 2014, 86, 229-235.	1.5	5
360	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1367-1381.	2.5	5

#	Article	IF	Citations
361	Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). Journal of Cancer Research and Clinical Oncology, 2014, 140, 1391-1397.	2.5	5
362	Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis. Annals of Hematology, 2016, 95, 1899-1901.	1.8	5
363	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. Blood, 2011, 118, 3770-3770.	1.4	5
364	Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose â€“ Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV. Blood, 2012, 120, 67-67.	1.4	5
365	Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. Leukemia, 0, , .	7.2	5
366	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia, 2022, 36, 1879-1886.	7.2	5
367	Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin. Annals of Hematology, 2016, 95, 355-357.	1.8	4
368	Reply to K.R. Hoffman. Journal of Clinical Oncology, 2017, 35, 567-568.	1.6	4
369	Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. Blood, 2004, 104, 2428-2428.	1.4	4
370	Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.. Blood, 2009, 114, 862-862.	1.4	4
371	Minimal Residual Disease in Hematological Malignancies. Acta Haematologica, 2004, 112, 5-7.	1.4	3
372	Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1845-1851.	2.5	3
373	Imatinib and Beyond â€“ Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. Onkologie, 2012, 35, 34-41.	0.8	3
374	Reply to H. Kantarjian et al. Journal of Clinical Oncology, 2014, 32, 3078-3078.	1.6	3
375	Sustained Molecular Responses with Interferon Î±2a Maintenance Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase Chronic Myelogenous Leukemia.. Blood, 2007, 110, 28-28.	1.4	3
376	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. Blood, 2008, 112, 448-448.	1.4	3
377	Molecular heterogeneity in complete cytogenetic responders after interferon-Î± therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood, 2000, 95, 62-66.	1.4	3
378	Genomic instability in context of the chromosomal theory. Cellular Oncology, 2008, 30, 503-4.	1.9	3

#	Article	IF	Citations
379	Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1569-1583.	2.5	3
380	Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 142, 162-164.	1.0	2
381	Prognostic Factors in Chronic Myeloid Leukemia (CML). Oncology Research and Treatment, 2008, 31, 576-578.	1.2	2
382	Short-Term Application of Magnetic Core-Shell Nanoparticlesâ€"Effect on Immune Cells. , 2010, , .		2
383	Lericheâ€™s syndrome and LÃ¶ffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome. Annals of Hematology, 2012, 91, 139-141.	1.8	2
384	Lower gastrointestinal bleeding in a patient with Crohnâ€™s disease and plasma cell leukemia in remission. Annals of Hematology, 2015, 94, 2063-2065.	1.8	2
385	Prognostic Impact of mRNA Expression Levels of HER1â€“4 (ERBB1â€“4) in Patients with Locally Advanced Rectal Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-9.	1.5	2
386	Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy. Haematologica, 2017, 102, e39-e42.	3.5	2
387	Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update. Hematologic Malignancies, 2021, , 105-117.	0.2	2
388	Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon Î±2a (PegasysÂ®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.. Blood, 2007, 110, 1027-1027.	1.4	2
389	Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2539-2548.	2.5	2
390	Reply to V. Pitini et al. Journal of Clinical Oncology, 2010, 28, e440-e440.	1.6	1
391	Ornithine transcarbamylase (OTC) deficiency based on a hemizygous p.R277W mutation causing life-threatening hyperammonemic crisis during treatment for Hodgkinâ€™s lymphoma. Annals of Hematology, 2011, 90, 857-859.	1.8	1
392	Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study. Annals of Hematology, 2013, 92, 907-915.	1.8	1
393	Die hÃmophagozytische Lymphohistiozytose (HLH) und das Makrophagenaktivierungssyndrom (MAS): Klinisches Erscheinungsbild und Diagnostik. Laboratoriums Medizin, 2013, 37, 217-225.	0.6	1
394	Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	1
395	Chronic Myelogeneous Leukemia. , 2015, , 85-99.		1
396	Comments on the Hammersmith policy. Seminars in Hematology, 2003, 40, 109-110.	3.4	0

#	Article	IF	Citations
397	Response: Drug treatment and allografting as first-line therapy in young patients with CML. Blood, 2007, 110, 4618-4619.	1.4	0
398	A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias. Leukemia Research, 2009, 33, e168-e169.	0.8	0
399	Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen LeukÃmie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leukemia: recommendations from a German expert panel. Laboratoriums Medizin, 2012, 36, .	0.6	0
400	Different clones of acute leukemia after successful treatment of Hodgkinâ€™s disease. Annals of Hematology, 2014, 93, 2077-2079.	1.8	0
401	Standardization of Molecular Monitoring for Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , 89-98.	0.2	0
402	Response-Related Predictors of Survival in CML. Hematologic Malignancies, 2016, , 129-145.	0.2	0
403	Detection of Enterococcus spp. in bronchoalveolar lavage fluid of patients with high-risk neutropenia: May it be ignored?. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1133-1136.	2.5	0
404	Erkrankungen des Blutes. , 2003, , 281-408.		0
405	PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.. Blood, 2004, 104, 4662-4662.	1.4	0
406	Chronische myeloproliferative Erkrankungen (CMPE). , 2007, , 377-400.		0
407	Campylobacter jejuni ssp. jejuni bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy. JMM Case Reports, 2015, 2, .	1.3	0
408	Chronische myeloproliferative Neoplasien (CMPN). , 2017, , 395-420.		0
409	Stammzellerkrankungen. , 2005, , 275-290.		0
410	Stammzellerkrankungen. , 2007, , 309-326.		0
411	Comments on the Hammersmith policy. Seminars in Hematology, 2003, 40, 109-110.	3.4	0
412	Chronische myeloische LeukÃmie: Absetzen der Therapie zurzeit nur experimentell. , 0, , .		0
413	Perspektivenwechsel: Ein Wirkstoff fÃ¼r mehrere Krebserkrankungen. , 0, , .		0